Who we are

Owen Mumford specialises in integrated design and build services from a broad range of self-injection platform devices for the pharmaceutical industry.

From the first automatic lancing device to our patented self-injection devices, with Owen Mumford you have access to unrivalled experience in designing, developing and delivering solutions to help you make adherence easier for patients.


With more than 65 years’ experience, your device is in trusted hands with Owen Mumford.

From day one, we will guide you throughout the development process; at every step, you will benefit from professional and supportive project management, processes, industrialisation and production for a smooth development and launch.

The springless, passive safety device for pre-filled syringes

Fully designed, developed and ready for commercial supply

Comfort

Large, ergonomic plunger head and a smooth, integrated finger flange, resulting in an integrated look and feel.

Secure plunger

Plunger cannot detach when removing the RNS.

Reduced risk

No compromise to sterility in assembly – plunger does not touch the bung.

User confidence

Syringe barrel is unobscured, allowing the user to check the contents of the syringe, and to confirm the full dose has been delivered.

Reliability

Prevention of occidental activation e.g. in transit.

Simple 2-step final sembly

Final assembly process is simple and outside of the sterile filling area.

Cost effective

Designed to work with standard, pre-filled syringes which means no change to existing primary container and minimises training costs.

Passive safety

Passive needle retraction means that the device is safe as soon as the plunger is fully depressed

Self-Injection Device Solutions 

Ensuring that patients are willing and able to inject their medication is key to their well-being. As pioneers in self-injection technologies, our experience enables us to effectively work with you to find the right drug delivery solution.


Please visit: omdevicesolutions.com

Go to article: Home | The dengue dilemma Go to article: In this issueGo to article: Owen MumfordGo to article: ContentsGo to article: Hapa Company Insight Go to article: Daiichi JitsugyoGo to article: NewsGo to article: EmbocapsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: The pharma industry briefingGo to article: Dow Europe Company InsightGo to article: Gerteis Company InsightGo to article: GerteisGo to article: The problem of manipulated data Go to article: Capsugel Company Insight Go to article: CapsugelGo to article: Timeline: the dengue vaccine dilemmaGo to article: TSS Company Insight Go to article: TSSGo to article: From evergreening to thicketing: exploring manipulation of the pharma patent sysGo to article: Emirates SkyCargoGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Swiss WorldCargoGo to article: Accurate BiometricsGo to article: Accurate Biometrics Company Insight Go to article: Nelson LabsGo to article: Treading the line: the challenge of transplant rejection drugsGo to article: Corbion PuracGo to article: Erdmann Design Company InsightGo to article: Erdmann Design SwitzerlandGo to article: Treating menopause: at last a non-hormonal alternative? Go to article: YourwayGo to article: ImmuMap Company Insight Go to article: ImmuMapGo to article: Drug repurposing: the industry’s all-rounder medicinesGo to article: FargoGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: One step closer to a Chlamydia vaccine Go to article: AralabGo to article: Synex SyntheticsGo to article: Deals in brief powered by GlobalDataGo to article: Charles Ischi Go to article: The key list powered by GlobalDataGo to article: Pharmaceutical Solutions IndustryGo to article: Clinichain Company Insight Go to article: ClinichainGo to article: SanofiGo to article: EventsGo to article: NymiGo to article: Modality SolutionsGo to article: PfanstiehlGo to article: Next issueGo to article: MimotopesGo to article: ICCI - International Cannabis and Cannabinoids Institute Go to article: ICCI